ANNA HESSE: Open Payments
NPI 1770368524 · NEW BRITAIN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,200 in 81 payments from 18 companies in 2025. Trend: 2023 $23 · 2024 $3,049 · 2025 $2,200
Food & beverage: $2,101Education: $99
| Company | Payments | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 7 | $337 |
| Actelion Pharmaceuticals US, Inc. | 7 | $267 |
| Amgen Inc. | 10 | $251 |
| PFIZER INC. | 12 | $240 |
| Novo Nordisk Inc | 4 | $192 |
| Novartis Pharmaceuticals Corporation | 8 | $186 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $123 |
| SCPHARMACEUTICALS INC. | 7 | $112 |
| Merck Sharp & Dohme LLC | 4 | $98 |
| Lilly USA, LLC | 3 | $77 |
Products named: Repatha, OPSUMIT, ELIQUIS, LEQVIO, Kerendia, Ozempic, AMVUTTRA, FUROSCIX.
Industry payments across CT — which companies pay providers there.
